Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Holding EXEL?
Track your performance easily
EXEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.02 - $37.59
Previous CloseN/A
Volume463.09K
Average Volume (3M)2.43M
Market Cap
$9.25B
Enterprise Value$6.57B
Total Cash (Recent Filing)$419.80M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)20.6
Beta0.34
Next Earnings
Feb 11, 2025EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding285,579,000
10 Day Avg. Volume3,245,919
30 Day Avg. Volume2,433,131
Standard Deviation0.11
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.44
Price to Cash Flow (P/CF)8.50
P/FCF Ratio8.80
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit3.74
Enterprise Value/Ebitda10.84
Forecast
1Y Price Target
$36.65Price Target Upside11.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Exelixis News
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsThe combination treatment of zanzalintinib and atezolizumab showed better treatment benefits than zanzalintinib alone.
Revenue PotentialAnalyst increases Cabometyx revenue trajectory by including revenue from emerging indications.
ValuationThe current valuation of the company is seen as undemanding, indicating potential for growth.
Bears Say
Efficacy DifferentiationThere is no clear safety and efficacy differentiation between Zanza and Cabo, though the data set is limited.
Regulatory ChallengesThe FDA announced an ADCOM for the cabozantinib review in neuroendocrine tumors due to uncertainties in the study outcomes.
Safety ConcernsSafety concerns, including serious adverse events, are likely to be discussed during the cabozantinib ADCOM.
---
Ownership Overview
2.89% Insiders
24.52% Mutual Funds
0.37% Other Institutional Investors
45.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $20.02 and its highest was $37.59 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $9.25B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Feb 11, 2025 which is in 11 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Oct 29, 2024. The company reported $0.4 earnings per share for the quarter, beating the consensus estimate of $0.339 by $0.061.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.44.
How many shares outstanding does Exelixis have?
Exelixis has 285,579,000 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.4 in its last earnings report, beating expectations of $0.339. Following the earnings report the stock price went up 12.913%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 659M.
---
Exelixis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.65 (11.30% Upside)
$36.65 (11.30% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 91%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.44%
12-Months-Change
Fundamentals
Return on Equity
20.52%
Trailing 12-Months
Asset Growth
-0.56%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EXEL Company Deck
---
EXEL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, highlighted by significant revenue growth, strategic collaborations, and a strong market position. Despite some challenges related to operating expenses and market competition, the forward-looking prospects, including the successful ANDA ruling and the partnership with Merck, signal a robust outlook for the company.Read More>---
EXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
---
EXEL Stock 12 Month Forecast
Average Price Target
$36.65
▲(11.30% Upside)
Technical Analysis
Incyte
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
CytomX Therapeutics
―
Argenx Se
―
Best Analysts Covering EXEL
1 Year
1 Year Success Rate
27/32 ratings generated profit
1 Year Average Return
+24.12%
reiterated a buy rating 5 days ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 84.38% of your transactions generating a profit, with an average return of +24.12% per trade.
---